Sexual Health Testing Market Share Analysis Report, 2023-2032

Sexual Health Testing Market - By Device Type (Laboratory Devices, Point of Care (PoC) Devices), By Application (Chlamydia, Gonorrhoea, Syphilis, Genital Herpes, Hepatitis B, HIV/AIDS), By End-use – Global Forecast to 2032

Report Content

Chapter 1&nbsp;&nbsp;&nbsp;Methodology &amp; Scope

1.1&nbsp;&nbsp;&nbsp; Methodology

1.2&nbsp;&nbsp;&nbsp; Market scope &amp; definitions

1.3&nbsp;&nbsp;&nbsp; Base estimates and calculations

1.3.1&nbsp;&nbsp;&nbsp; North America

1.3.2&nbsp;&nbsp;&nbsp; Europe

1.3.3&nbsp;&nbsp;&nbsp; Asia Pacific

1.3.4&nbsp;&nbsp;&nbsp; Latin America

1.3.5&nbsp;&nbsp;&nbsp; MEA

1.4&nbsp;&nbsp;&nbsp; Forecast calculations

1.5&nbsp;&nbsp;&nbsp; Data validation

1.6&nbsp;&nbsp;&nbsp; COVID-19 impact analysis at global level

1.7&nbsp;&nbsp;&nbsp; Data sources

1.7.1&nbsp;&nbsp;&nbsp; Secondary

1.7.1.1&nbsp;&nbsp;&nbsp;Paid sources

1.7.1.2&nbsp;&nbsp;&nbsp;Unpaid sources

1.7.2&nbsp;&nbsp;&nbsp; Primary

Chapter 2&nbsp;&nbsp;&nbsp;Executive Summary

2.1&nbsp;&nbsp;&nbsp; Sexual health testing market industry 3600&nbsp;&nbsp;synopsis, 2018 - 2032

2.1.1&nbsp;&nbsp;&nbsp; Business trends

2.1.2&nbsp;&nbsp;&nbsp; Regional trends

2.1.3&nbsp;&nbsp;&nbsp; Device type trends

2.1.4&nbsp;&nbsp;&nbsp; Application trends

2.1.5&nbsp;&nbsp;&nbsp; End-use trends

Chapter 3&nbsp;&nbsp;&nbsp;Sexual Health Testing Industry Insights

3.1&nbsp;&nbsp;&nbsp; Industry segmentation

3.2&nbsp;&nbsp;&nbsp; Industry ecosystem analysis

3.3&nbsp;&nbsp;&nbsp; Industry impact forces

3.3.1&nbsp;&nbsp;&nbsp; Growth drivers

3.3.1.1&nbsp;&nbsp;&nbsp;Surge in prevalence of sexually transmitted diseases (STDs)

3.3.1.2&nbsp;&nbsp;&nbsp;Increasing government initiatives towards STD&#39;s

3.3.1.3&nbsp;&nbsp;&nbsp;Technological advancements in sexually transmitted disease diagnosis

3.3.1.4&nbsp;&nbsp;&nbsp;Rising awareness regarding STDs and its diagnosis

3.3.2&nbsp;&nbsp;&nbsp; Industry pitfalls &amp; challenges

.3.3.2.1. &nbsp;&nbsp;&nbsp;Social taboo related to STDs

3.3.2.2&nbsp;&nbsp;&nbsp;Lack of reimbursement scenario

3.4&nbsp;&nbsp;&nbsp; Growth potential analysis

3.4.1&nbsp;&nbsp;&nbsp; By device type

3.4.2&nbsp;&nbsp;&nbsp; By application

3.4.3&nbsp;&nbsp;&nbsp; By end-use

3.5&nbsp;&nbsp;&nbsp; COVID- 19 impact analysis

3.6&nbsp;&nbsp;&nbsp; Regulatory landscape

3.6.1&nbsp;&nbsp;&nbsp; U.S.

3.6.2&nbsp;&nbsp;&nbsp; Europe

3.7&nbsp;&nbsp;&nbsp; Porter&#39;s analysis

3.8&nbsp;&nbsp;&nbsp; PESTEL analysis

Chapter 4&nbsp;&nbsp;&nbsp;Competitive landscape

4.1&nbsp;&nbsp;&nbsp; Introduction

4.2&nbsp;&nbsp;&nbsp; Company matrix analysis, 2021

4.3&nbsp;&nbsp;&nbsp; Competitive dashboard

4.4&nbsp;&nbsp;&nbsp; Company market share, 2021

4.5&nbsp;&nbsp;&nbsp; Competitive analysis of major market players

4.6&nbsp;&nbsp;&nbsp; Competitive positioning matrix

4.7&nbsp;&nbsp;&nbsp; Strategic outlook matrix

Chapter 5&nbsp;&nbsp;&nbsp;Sexual Health Testing Market and Forecast, By Device Type (USD Million)

5.1&nbsp;&nbsp;&nbsp; Key trends, by device type

1.1&nbsp;&nbsp;&nbsp; Laboratory devices

1.1.1&nbsp;&nbsp;&nbsp; PCR

1.1.2&nbsp;&nbsp;&nbsp; Flow cytometers

1.1.3&nbsp;&nbsp;&nbsp; Enzyme linked immunosorbent assay (ELISA)

1.1.4&nbsp;&nbsp;&nbsp; Others

1.2&nbsp;&nbsp;&nbsp; Point of care (PoC) devices

1.2.1&nbsp;&nbsp;&nbsp; Microfluidics and immunochromatographic testing (ICT)

1.2.2&nbsp;&nbsp;&nbsp; Rapid diagnostic kits

Chapter 6&nbsp;&nbsp;&nbsp;Sexual Health Testing Market and Forecast, By Application (USD Million)

2.1&nbsp;&nbsp;&nbsp; Key trends, by application

2.2&nbsp;&nbsp;&nbsp; Chlamydia

2.3&nbsp;&nbsp;&nbsp; Gonorrhoea

2.4&nbsp;&nbsp;&nbsp; Syphilis

2.5&nbsp;&nbsp;&nbsp; Genital herpes

2.6&nbsp;&nbsp;&nbsp; Hepatitis B

2.7&nbsp;&nbsp;&nbsp; HIV/AIDS

2.8&nbsp;&nbsp;&nbsp; Others

Chapter 7&nbsp;&nbsp;&nbsp;Sexual Health Testing Market and Forecast, By End-use (USD Million)

3.1&nbsp;&nbsp;&nbsp; Key trends, by end-use

3.2&nbsp;&nbsp;&nbsp; Hospitals

3.3&nbsp;&nbsp;&nbsp; Diagnostic centers

3.4&nbsp;&nbsp;&nbsp; Others

Chapter 8&nbsp;&nbsp;&nbsp;Sexual Health Testing Market and Forecast, By Region (USD Million)

4.1&nbsp;&nbsp;&nbsp; Key regional trends

4.2&nbsp;&nbsp;&nbsp; North America

4.2.1&nbsp;&nbsp;&nbsp; U.S.

4.2.2&nbsp;&nbsp;&nbsp; Canada

4.3&nbsp;&nbsp;&nbsp; Europe

4.3.1&nbsp;&nbsp;&nbsp; Germany

4.3.2&nbsp;&nbsp;&nbsp; UK

4.3.3&nbsp;&nbsp;&nbsp; France

4.3.4&nbsp;&nbsp;&nbsp; Spain

4.3.5&nbsp;&nbsp;&nbsp; Italy

4.3.6&nbsp;&nbsp;&nbsp; Russia

4.3.7&nbsp;&nbsp;&nbsp; Poland

4.3.8&nbsp;&nbsp;&nbsp; Switzerland

4.3.9&nbsp;&nbsp;&nbsp; Norway

4.3.10&nbsp;&nbsp;&nbsp; Finland

4.3.11&nbsp;&nbsp;&nbsp; Sweden

4.3.12&nbsp;&nbsp;&nbsp; Denmark

4.3.13&nbsp;&nbsp;&nbsp; The Netherlands

4.4&nbsp;&nbsp;&nbsp; Asia Pacific

4.4.1&nbsp;&nbsp;&nbsp; China

4.4.2&nbsp;&nbsp;&nbsp; Japan

4.4.3&nbsp;&nbsp;&nbsp; India

4.4.4&nbsp;&nbsp;&nbsp; Australia

4.4.5&nbsp;&nbsp;&nbsp; South Korea

4.4.6&nbsp;&nbsp;&nbsp; Taiwan

4.4.7&nbsp;&nbsp;&nbsp; Indonesia

4.4.8&nbsp;&nbsp;&nbsp; Vietnam

4.5&nbsp;&nbsp;&nbsp; Latin America

4.5.1&nbsp;&nbsp;&nbsp; Brazil

4.5.2&nbsp;&nbsp;&nbsp; Mexico

4.5.3&nbsp;&nbsp;&nbsp; Argentina

4.5.4&nbsp;&nbsp;&nbsp; Colombia

4.5.5&nbsp;&nbsp;&nbsp; Chile

4.6&nbsp;&nbsp;&nbsp; Middle East &amp; Africa

4.6.1&nbsp;&nbsp;&nbsp; South Africa

4.6.2&nbsp;&nbsp;&nbsp; Saudi Arabia

4.6.3&nbsp;&nbsp;&nbsp; UAE

4.6.4&nbsp;&nbsp;&nbsp; Israel

Chapter 9&nbsp;&nbsp;&nbsp;Company Profiles

5.1&nbsp;&nbsp;&nbsp; bioM&eacute;rieux SA

5.2&nbsp;&nbsp;&nbsp; Hologic, Inc.

5.3&nbsp;&nbsp;&nbsp; OraSure Technologies, Inc.

5.4&nbsp;&nbsp;&nbsp; Bio-Rad Laboratories, Inc.

5.5&nbsp;&nbsp;&nbsp; Abbott Laboratories

5.6&nbsp;&nbsp;&nbsp; Merck &amp; Co. Inc.

5.7&nbsp;&nbsp;&nbsp; Johnson &amp; Johnson Services, Inc

5.8&nbsp;&nbsp;&nbsp; GlaxoSmithKline Plc.

5.9&nbsp;&nbsp;&nbsp; Allergen

5.10&nbsp;&nbsp;&nbsp; Bayer AG

5.11&nbsp;&nbsp;&nbsp; Bristol-Myers Squibb Company

5.12&nbsp;&nbsp;&nbsp; Bausch Health Companies Inc.

5.13&nbsp;&nbsp;&nbsp; Boehringer Ingelheim International GmbH

5.14&nbsp;&nbsp;&nbsp; Sorrento Therapeutics, Inc.

5.15&nbsp;&nbsp;&nbsp; WEX Pharmaceuticals Inc.

5.16&nbsp;&nbsp;&nbsp; Zynerba Pharmaceuticals, Inc.

5.17&nbsp;&nbsp;&nbsp; Medtronic Inc.

5.18&nbsp;&nbsp;&nbsp; Boston Scientific Corporation

5.19&nbsp;&nbsp;&nbsp; Halyard Health, Inc.

5.20&nbsp;&nbsp;&nbsp; Neurotech Na, Inc.

&nbsp;&nbsp;&nbsp;

Sexual Health Testing Market

Request Discount

Industries

Information

Link

Global Headquarters